From Yahoo Finance: 2025-06-11 19:40:00

Insmed Incorporated (NASDAQ:INSM) is one of the 13 Biotech Stocks with Huge Upside Potential. Analyst Kelly Shi of Jefferies recommends a buy, confident in TPIP treatment’s Phase 2 data for pulmonary arterial hypertension, anticipating a 20% decrease in pulmonary vascular resistance. Wells Fargo also reaffirmed a Buy rating on June 4 with a $107 price target.

Shi notes TPIP’s once-daily dosage advantage over Tyvaso’s four-times-daily schedule, potentially increasing adherence. Interim study results show benefits in six-minute walk distance. Market penetration potential could lead to valuation increase for Insmed Incorporated (NASDAQ:INSM), potentially changing PAH treatment methods.

Insmed Incorporated (NASDAQ:INSM) focuses on improving the lives of individuals with serious and rare diseases. While INSM shows investment potential, other AI stocks may offer greater upside. For those seeking an undervalued AI stock with benefits from Trump-era tariffs and onshoring trend, consider the best short-term AI stock.

Read more: Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)